FANGDA PARTNERS 上海市方达律师事务所 关于无锡药明康德新药开发股份有限公司 回购注销部分限制性股票相关事宜的法律意见书 致：无锡药明康德新药开发股份有限公司 上海 Shanghai·北京 Beijing·深圳 Shenzhen·广州 Guangzhou·香港 HongKong http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电话 Tel.: 86-21-2208-1166 邮政编码：200041 传真 Fax: 86-21-5298-5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai 200041, PRC 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国法律执业 资格的律师事务所。根据相关法律顾问协议，本所现就无锡药明康德新药开发股 份有限公司（以下简称"公司"）2019 年限制性股票与股票期权激励计划项目（以 下简称"2019 年激励计划"）部分限制性 ...

关于 2019 年限制性股票与股票期权激励计划首次授予股票期权 2023 年第三季度自主行权结果暨股份变动公告 证券代码：603259 证券简称：药明康德 公告编号：临 2023-060 无锡药明康德新药开发股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次行权股票数量：无锡药明康德新药开发股份有限公司（以下简称 "公司"）2023 年第三季度激励对象行权且完成股份过户登记的股票期权数量 为 533,925 股，占本次行权股票期权总量的 31.58%。截至 2023 年 9 月 30 日，累 计行权且完成股份过户登记的股票期权数量为 1,027,032 股，占本次行权股票期 权总量的 60.74%。 本次行权股票上市流通时间：公司本次行权采用自主行权模式，激励对 象行权所得股票于行权日（T 日）后的第一个交易日（T+1 日）到达股票账户， 并于第二个交易日（T+2 日）上市交易。 一、本次行权的决策程序及相关信息披露 1、2019 年 7 月 19 日，公司召开第一届董事会第三十二次会议和第一届 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2023年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 402,543,650 | RMB | | 1 | RMB | | 402,543,650 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 402,543,650 | RMB | | 1 | RMB | | 402,543,650 | | 2. 股份分類 | 普通股 ...

证券代码： 603259 证券简称：药明康德 公告编号：临 2023-059 无锡药明康德新药开发股份有限公司 本次多肽生产车间产能扩建项目将大幅提升本公司的多肽生产产能以及 WuXi TIDES 平台能力，巩固和提升本公司在全球范围内的市场竞争力，支持本 公司长远发展，同时亦可更好地满足全球合作伙伴在多肽药物开发与生产方面 日益增长的需求，为广大患者带来更多创新疗法。 三、风险提示 本次多肽生产车间产能扩建项目完成后完全达产、释放产能尚需一定时间， 后续生产亦可能面临潜在风险，包括但不限于未来可能存在市场环境变化、行 1 业政策变化、竞争加剧、终端需求调整等风险。敬请广大投资者注意投资风险。 特此公告。 下属子公司合全药业多肽生产车间产能扩建项目的自愿性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 目前无锡药明康德新药开发股份有限公司（以下简称"本公司"）下属子公 司上海合全药业股份有限公司（以下简称"合全药业"）在常州和泰兴两个生产 基地进行多肽生产车间产能扩建项目（以下简称"本次多肽生产车间产能扩建 项目"）。本 ...

二、本次限制行权期为 2023 年 10 月 1 日至 2023 年 10 月 30 日（包含首尾 两日），在此期间全部激励对象将限制行权。 三、公司将按照有关规定及时办理限制行权相关事宜。 特此公告。 证券代码：603259 证券简称：药明康德 公告编号：临 2023-058 无锡药明康德新药开发股份有限公司 关于 2019 年限制性股票与股票期权激励计划首次授予股票期权 第三个行权期限制行权期间的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司股权激励管理办法》、上海证券交易所《上市公司自律监管 指南第八号——股权激励计划股票期权自主行权》《无锡药明康德新药开发股份 有限公司 2019 年限制性股票与股票期权激励计划（草案）》及中国证券登记结 算有限责任公司上海分公司（以下简称"中证登上海分公司"）关于股票期权自 主行权的相关规定，并结合无锡药明康德新药开发股份有限公司（以下简称"公 司"）2023 年第三季度报告披露计划，现对公司 2019 年限制性股票与股票期权 激励计划首次授予股票期权（以下 ...

Financial Performance - Revenue for the first half of 2023 reached RMB 18,871.3 million, representing a 6.3% increase from RMB 17,756.3 million in the same period of 2022[8]. - Gross profit increased by 17.6% to RMB 7,555.7 million, with a gross margin of 40.0%, up from 36.2% in the previous year[8]. - Net profit attributable to shareholders rose by 14.6% to RMB 5,313.1 million, with a net profit margin of 28.2%, compared to 26.1% in 2022[8]. - Adjusted net profit attributable to shareholders was RMB 5,094.7 million, an 18.5% increase from RMB 4,300.7 million in the prior year[8]. - The company achieved revenue of RMB 18,871.3 million, a year-on-year increase of 6.3%, and net profit attributable to shareholders of RMB 5,313.1 million, up 14.6% year-on-year[9]. - The company reported a basic earnings per share of RMB 1.81, reflecting a 13.8% increase from RMB 1.59 in the same period last year[8]. - The adjusted basic earnings per share was RMB 1.73, an increase of 17.7% from RMB 1.47 in the previous year[8]. - Net profit for the period increased by 14.6% to RMB 5,356.9 million, with a net profit margin rising from 26.3% to 28.4%[24]. - The total comprehensive income for the period attributable to equity holders was RMB 4,806,967 thousand, an increase of 10.7% from RMB 4,342,460 thousand in the prior year[194]. Assets and Liabilities - Total assets as of June 30, 2023, amounted to RMB 69,319.1 million, a 7.2% increase from RMB 64,690.3 million at the end of 2022[8]. - Total liabilities increased by 7.6% to RMB 19,120.4 million, compared to RMB 17,763.7 million in the previous year[8]. - Cash and cash equivalents rose by 20.1% to RMB 9,585.0 million, up from RMB 7,983.9 million at the end of 2022[8]. - The debt-to-asset ratio remained stable at 27.6%, slightly up from 27.5% at the end of 2022[8]. - As of June 30, 2023, total assets amounted to RMB 41,739,069 thousand, an increase from RMB 40,693,101 thousand as of December 31, 2022, representing a growth of approximately 2.57%[195]. - The company's net equity as of June 30, 2023, was RMB 50,198,782 thousand, compared to RMB 46,926,673 thousand at the end of 2022, marking an increase of around 4.83%[196]. - The total liabilities decreased from RMB 14,499,361 thousand to RMB 16,363,159 thousand, indicating a rise of approximately 12.87%[195]. Revenue Sources and Client Growth - The company added over 600 new clients in the first half of 2023, with active clients exceeding 6,000 over the past 12 months, leading to a 25% year-on-year increase in orders excluding COVID-19 commercialization projects[9]. - Revenue from U.S. clients reached RMB 12.37 billion, a 42% year-on-year increase when excluding COVID-19 projects; revenue from European clients was RMB 2.22 billion, up 19%[9]. - The WuXi Chemistry segment generated revenue of RMB 13,467.2 million, a 3.8% increase year-on-year, with a strong growth of 36.1% when excluding COVID-19 projects[10]. - The WuXi Testing segment reported revenue of RMB 3,091.0 million, an 18.7% year-on-year increase, with laboratory analysis and testing services contributing RMB 2,250 million, up 18.8%[12]. - The WuXi Biology segment achieved revenue of RMB 1,232.6 million, a 13.0% increase year-on-year, with new molecular-related revenue growing by 51%[13]. - The company’s D&M (Development and Manufacturing) revenue reached RMB 9.67 billion, a 2.1% increase year-on-year, with a strong growth of 54.5% when excluding COVID-19 projects[11]. - Approximately 99% of the company’s revenue came from existing clients, totaling RMB 18.65 billion, a 30% year-on-year increase when excluding COVID-19 projects[9]. Operational Efficiency and Cost Management - The net cash flow from operating activities for the six months ended June 30, 2023, was RMB 5,340.7 million, an increase of 41.7% compared to RMB 3,767.9 million for the same period in 2022, driven by stable revenue collection and optimized working capital management[25]. - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,307.8 million, a decrease of 65.3% from RMB 3,770.1 million in the same period of 2022, primarily due to timing differences in project settlements leading to reduced capital expenditures[26]. - The net cash used in financing activities for the six months ended June 30, 2023, was RMB 2,612.8 million, an increase of 129.7% compared to RMB 1,137.6 million for the same period in 2022, mainly due to increased cash dividend payments during the reporting period[27]. - The company reported a decrease in cash outflow for the purchase of property, plant, and equipment to RMB 2,296,036 thousand in 2023 from RMB 4,359,857 thousand in 2022, indicating improved capital efficiency[199]. Research and Development - Research and development expenses for the period were RMB 667,045 thousand, slightly up from RMB 657,200 thousand in the previous year[193]. - The company is developing multiple potential FIC/BIC molecules for various cancers, with the first clinical trial application for the brain tumor probe BR-02 accepted by CDE and the BR-11 tumor treatment drug set to start IIT clinical trials in Q3 2023[41]. - The company is committed to leveraging cutting-edge technologies, such as medical big data and automated laboratories, to enhance operational efficiency and reduce drug development barriers[44]. Shareholder and Incentive Plans - The company has established a share incentive plan in place to motivate and retain employees[181]. - The 2022 profit distribution plan was approved, with a cash dividend of RMB 8.9266 per 10 shares to shareholders listed on June 13, 2023[52]. - The board approved the 2023 H-share incentive trust plan on April 24, 2023, to enhance the company's compensation policy[164]. - The company aims to enhance its long-term incentive mechanism to attract and retain talent, ensuring sustainable development[116]. Market Outlook and Strategic Goals - The global pharmaceutical market is expected to continue growing due to economic development, population growth, aging, increased healthcare spending, and rising health awareness[60]. - The demand for pharmaceutical R&D services is anticipated to grow rapidly as large pharmaceutical companies increase outsourcing and small to medium-sized companies seek integrated R&D services[60]. - The company aims to become a leading platform in the global pharmaceutical industry, providing comprehensive and integrated drug R&D and production services[61]. - In 2023, the company will focus on building capabilities and scale, enhancing its integrated enabling platform to support innovation for clients[62]. Risks and Challenges - The pharmaceutical R&D services industry is highly regulated, and any failure to adapt to changes in industry policies and regulations could have a negative impact on the company's operations[70]. - The company faces intensified competition in the global pharmaceutical R&D services market, particularly from large pharmaceutical companies and specialized CRO/CDMO institutions, which may possess stronger financial and technical capabilities[71]. - The loss of core technical personnel poses a risk to the company's competitive advantage and ongoing profitability, particularly if compensation and incentive mechanisms are not competitive[74].

无锡药明康德新药开发股份有限公司 简式权益变动报告书 上市公司名称：无锡药明康德新药开发股份有限公司 股票上市地点：上海证券交易所、香港联合交易所有限公司 股票简称：药明康德 股票代码：603259.SH、02359.HK | 信息披露义务人 | | 住所 Unit 826, 8/F, Ocean | | 通讯地址 | | | | --- | --- | --- | --- | --- | --- | --- | | Limited | G&C IV Hong Kong | Centre, Harbour City, 5 | | | | | | | | Canton Road, | | 中国上海外高 | | Tst, | | | | Kowloon, Hong Kong | | 桥富特中路 | | | | G&C V Limited | | PO Box 309, Ugland | | 号 | | | | G&C VI Limited | | House, Grand Cayman, | | | 288 | | | G&C VII Limited | | KY1-1104, Cayman | | | | | ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-057 无锡药明康德新药开发股份有限公司 关于股东权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司收到公司实际控制人 Ge Li（李革）、张朝晖和刘晓钟（以下合称"实 际控制人"）控制或与实际控制人签署一致行动协议或签署投票委托书的 22 名 股东（以下合称为"信息披露义务人"）于 2023 年 8 月 30 日出具的《无锡药明 康德新药开发股份有限公司简式权益变动报告书》，现就《前次权益变动报告》 披露以来的本次权益变动相关情况公告如下： 一、本次权益变动基本情况 1、信息披露义务人基本情况 本次权益变动的信息披露义务人为公司实际控制人控制的股东、与实际控制 人签署一致行动协议的股东、与实际控制人签署投票委托书的股东，即 G&C IV Hong Kong Limited（以下简称"G&C IV"）、G&C V Limited（以下简称"G&C V"）、G&C VI Limited（以下简称"G&C VI"）、G&C ...

证券代码：603259 证券简称：药明康德 公告编号：临 2023-056 无锡药明康德新药开发股份有限公司 股东减持股份进展暨权益变动比例超过 1%的 提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东持股的基本情况 本次减持计划实施前，无锡药明康德新药开发股份有限公司（以下简称"公 司"）实际控制人控制的股东及与实际控制人签署一致行动协议的股东（以下简 称"减持股东"）合计持有公司 A 股股份 647,696,535 股，占公司截至 2023 年 4 月 17 日总股本的 21.83%。该等股份均为公司首次公开发行 A 股股票并上市前所 取得的股份及上市后权益分派资本公积转增股本方式取得的股份，均为无限售条 件流通股。 本次减持计划的主要内容 | 股东名称 | 股东身份 | 持股数量（股） | 持股比例 | 当前持股股份来源 | | | | --- | --- | --- | --- | --- | --- | --- | | 公司实际控制人控制 | | | | IPO 前 得 | ...